SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Inclusion Criteria: Patients who meet the following criteria at the start of treatment are eligible for the study: * Receiving stable treatment with anti-hypertensive including ARB for at least 8 weeks at baseline (0W). * Receiving stable anti-diabetic treatment with/without anti-diabetics for at least 8 weeks at baseline (0W). * HbA1c\>=6.0%, \<10% * Seated office SBP 130-159mmHg or DBP 80-99mmHg * Nocturnal hypertension (SBP\>=115 mmHg) as measured by Home BP during 5days before baseline (0W). * Age\>=20 Exclusion Criteria: Patients who meet any of the following criteria are not eligible for the study: * History of hypersensitivity to empagliflozin * Breast-feeding, pregnant, possibly pregnant, or plan to become pregnant * Treated with insulin or SU * With renal dysfunction (eGFR\<45mL/min/1.73m2) * With liver dysfunction (AST or ALT is 3 times higher than reference value) * Hypotension (systolic blood pressure \< 90 mmHg) * With pituitary gland dysfunction or adrenal gland dysfunction * Heart failure patients whose NYHA class is IV * Deemed ineligible for the study due to another reason by investigator * History of diabetic ketoacidosis or diabetic come within 3 months before enrollment * History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment * Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment * Patients received SGLT2 inhibitor within 8 weeks before enrollment